Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levine, M.
Right arrow Articles by Sheppard, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levine, M.
Right arrow Articles by Sheppard, I.
NEUROLOGY 1985;35:562
© 1985 American Academy of Neurology

Differential effect of cimetidine on serum concentrations of carbamazepine and phenytoin

Marc Levine, PhD, Michael W. Jones, MD, FRCP(C) and Ian Sheppard, BSc(Pharm)

Faculties of Pharmaceutical Sciences (Dr. Levine and Mr. Sheppard) and Medicine (Dr. Jones), University of British Columbia, and the Divisions of Clinical Pharmacy (Dr. Levine) and Neurology (Dr. Jones), and the Department of Pharmacy (Mr. Sheppard), Shaughnessy Hospital, Vancouver, B.C., Canada.

Cimetidine is an inhibitor of drug metabolism. We studied the effects of cimetidine (1,200 mg/d) on steady-state serum concentrations of carbamazepine and phenytoin in 11 epileptic volunteers. The mean serum carbamazepine concentration was unchanged after 7 days of cimetidine treatment. Five subjects were taking phenytoin concurrently; their mean serum phenytoin concentration was significantly increased after 7 and 10 days of cimetidine treatment and returned to baseline 2 weeks after cimetidine was discontinued. Cimetidine apparently inhibits the clearance of phenytoin but not of carbamazepine in adults on chronic therapy.

Address correspondence and reprint requests to Dr. Levine, Faculty of Pharmaceutical Sciences, 2146 East Mall, The University of British Columbia, Vancouver, BC V6T 1W5, Canada.

Supported by grants from Smith, Kline and French Canada Ltd., and the British Columbia Medical Services Foundation.

Accepted for publication August 10, 1984.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by AAN Enterprises, Inc.